Our outpatient oncology team has noticed an increased rate of cutaneous reactions to docetaxel not related to a specific manufacturer or lot number, some requiring ED transfer or other intervention/escalation of care.
The package insert includes a warning regarding cutaneous reactions, but we were wondering if anyone else is experiencing a similar trend. We have assessed our docetaxel utilization to see if it might be related to an increased utilization over the past few weeks, but our utilization has actually decreased.
Gina Gayed, PharmD, BCPS, CPPS
Medication Safety Officer
Wellstar Health System